The global large molecule bioanalytical testing service market is anticipated to expand at substantial CAGR during forecast period, between 2020 and 2027. Large molecule bioanalysis operates in the field of analytical chemistry. These large drug molecules are effective in treating a range of indications of chronic illness. The growth of the biopharmaceutical R&D pipeline has boosted the demand for large molecules bioanalytical testing services; therefore, many biopharmaceutical companies are introducing large-scale outsourcing services. Bioanalytical research of big molecules has always been a challenge for the biopharmaceutical industry. Various specialized methods are HRMS, scale exclusion affinity chromatography, ligand binding assays (LBA) and Maldi-TOF-MS. Bioanalytical studies for large molecules can easily be conducted using these advanced techniques.
Market Trends, Drivers, Restraints, and Opportunities:
- Technological advancements in bioanalytical research for the large molecule fuels market growth.
- Increase in emphasis on analytical testing, rise in research & development costs in the pharmaceutical and biopharmaceutical industries, and growth in the demand for analytical test outsourcing fuel market growth.
- Compliance issues while outsourcing large molecule bioanalytical testing services are expected to hamper the market.
Scope of the report:
The report on large molecule bioanalytical testing service market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Base Year
|
2019
|
Historic Data
|
2017 & 2018
|
Forecast Period
|
2020–2027
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
|
Large Molecule Bioanalytical Testing Service Market Segment Insights:
The clinical segment is projected to hold significant market share
In the terms of phases, the large molecule bioanalytical testing service market has been segmented into preclinical, with antibody, without antibody (ELISA-based assay), and clinical. The clinical segment is projected to grow at a significant pace during the forecast period due to the growing prevalence of chronic diseases in developing countries and rising need for clinical trials.
Antidrug antibodies (ADA) segment held substantial market share in 2019
Based on types, the market is fragmented into pharmacokinetics, ADA, and others. The antidrug antibodies (ADA) segment holds significant market share is projected to expand at rapid rate during the forecast period. ADA assays promote large molecular drug production.
Bioavailability segment is expected to grow during the forecast period
On the basis of test types, the large molecule bioanalytical testing service market has been segregated into ADME, PK, PD, bioavailability, bioequivalence, and other tests. The bioavailability segment is expected to hold significant market share during the forecast period. The bioavailability of a pharmaceutical medicine partly depends on the characteristics of a dosage form. It plays a key role in pharmacokinetics, as it is taken non-intravenous dose calculations.
Surge in prevalence of cancer fuels the oncology segment
In terms of therapeutic areas, the market is classified as oncology, infectious diseases, cardiology, neurology, and others. The oncology segment holds a significant share of the market due to high prevalence of cancer across the globe. The cardiology segment is projected to expand at substantial CAGR during the forecast period.
Small and Medium Enterprises (SMEs) segment holds significant market share
Based on end-users, the large molecule bioanalytical testing service market is bifurcated into SME and large firm. Both segments are further divided into CROs & CMOs, sponsor organizations, and others. The development of biopharmaceutical inventions in the US, for example, due to increase in the demand for SMEs for products, processes, and services.
North America dominates the global market
In terms of regions, the global large molecule bioanalytical testing service market is split into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounts for a considerable share of the large molecule bioanalytical testing service market. The US has numerous manufacturing facilities for extremely effective, complex, and high-end medications. The market is expected to develop significantly in the US during the forecast period due to the rapid increase in biologic production to meet the growing demand for efficient medical care in the country, strong R&D, and promotion of new therapies.
Segments
By Phases
- Preclinical
- With Antibody
- Without Antibody (ELISA Based Assay)
- Clinical
By Types
- Pharmacokinetics
- ADA
- Others
By Test Types
- ADME
- PK
- PD
- Bioavailability
- Bioequivalence
- Other Tests
By Therapeutic Areas
- Oncology
- Infectious Diseases
- Cardiology
- Neurology
- Others
By End-users
- SMEs
- CROs & CMOs
- Sponsor Organizations
- Others (Academic institute, etc.)
- Large Firms
- CROs & CMOs
- Sponsor Organizations
- Others (Academic institute, etc.)
By Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Key Players in the market
- Charles River Laboratory International
- Covance Inc.
- ICON Plc
- Intertek Group plc
- IQVIA
- Pace Analytical Services LLC
- PPD INC.
- SGS SA
- Syneos Health
- Toxikon
Competitive Landscape
Key players in the large molecule bioanalytical testing service market include Charles River Laboratory International, Covance, Inc., ICON Plc, Intertek Group plc, IQVIA, Pace Analytical Services LLC, PPD, INC., SGS SA, Syneos Health, and Toxikon. Mergers & acquisitions, collaborations, agreements, and partnerships are some growth strategies adopted by these players to strengthen their geographical presence.